


AMENDMENTS TO THE CLAIMS

Please delete all prior lists of claims in the application and insert the following list of claims:

1-4 (CANCELED).

5. (CURRENTLY AMENDED) A compound of structural formula (I) for use as an activator of histone acetyltransferases:



wherein:

R¹ is selected from the group consisting of **hydrogen**, C₁- to C₁₆-alkyl and C₁- to C₁₆-alkene;

R² is selected from the group consisting of hydrogen, and C₁- to C₆-alkyl;

R³ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁴ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁵ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃,

F, Cl, I, and;

R⁶ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁷ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN; and

R⁸, R⁹, and R¹⁰ are independently selected from the group consisting of hydrogen, C₁- to C₁₆-alkyl, C₁- to C₁₆-alkene, and C₁- to C₁₆-alkoxy; and salts thereof.

6. (CURRENTLY AMENDED) The compound of claim 5, wherein:

R¹ is selected from the group consisting of ~~methyl, ethyl~~, n-propyl, isopropyl, n-butyl, t-butyl, C₈H₁₈, C₁₅H₂₆, C₁₅H₂₈, C₁₅H₃₀, and C₁₅H₃₂;

R² is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl;

R³ is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁴ is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁵ is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF₃, CCl₃, Cl₃, F, Cl, and I;

R⁶ is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN; and

R⁷ is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl and t-butyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN.


7. (PREVIOUSLY PRESENTED) A compound selected from the group consisting of:

N-(4-nitro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;

N-(4-nitro-3-trifluoromethyl-phenyl)-2-propoxy-benzamide;
 N-(4-nitro-3-trifluoromethyl -phenyl)-2-isopropoxy-benzamide;
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-6-pentadecyl-benzamide;
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-n-propoxy-6-pentadecyl-benzamide;
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide;
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-methoxy-benzamide;
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-methoxy-benzamide;
 N-(4-chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide;
 N-(4-cyano-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide;
 N-(4-nitro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
 N-(4-nitro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-
 benzamide;
 N-(4-fluoro-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;
 N-(4-fluoro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
 N-(4-fluoro-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;
 N-(4-fluoro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
 N-(4-iodo-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;
 N-(4-iodo-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
 N-(4-iodo-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;
 N-(4-iodo-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
 N-(4-bromo-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;

N-(4-bromo-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
 N-(4-bromo-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;
 N-(4-bromo-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
 N-(4-carboxylic-3-trifluoromethyl-phenyl)-2-methoxy-6-pentadecyl-benzamide;
 N-(4- carboxylic -3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide;
 N-(4- carboxylic -3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide;
 N-(4- carboxylic-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
 N-(4-nitro-3-trifluoromethyl-phenyl)-2-propoxy-6-pentadecyl-benzamide; and
 N-(4-nitro-3-trifluoromethyl-phenyl)-2-isopropoxy-6-pentadecyl-benzamide;
 and salts thereof.

8. (CURRENTLY AMENDED) A compound of structural formula (I):



wherein R¹, is selected from the group consisting of C₁₄- to C₁₆-alkyl and C₁₄- to C₁₆-alkenyl R², R⁸, R⁹ and R¹⁰ are defined such that the ring moiety to which R¹, R², R⁸, R⁹ and R¹⁰ are attached defines a moiety selected from the group consisting of anacardic acid, anacardic aldehyde, anacardic alcohol, 2-ethoxy-6-pentadecyl-benzoic acid, cardanol, and cardol;

R₂ is selected from the group consisting of hydrogen, methyl, and ethyl;

R³ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁴ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁵ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, and I;

R⁶ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN; ~~and~~


R⁷ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁸ and R¹⁰ are hydrogen; and

R⁹ is selected from the group consisting of hydrogen and hydroxy;

and salts thereof.

9. (CURRENTLY AMENDED) A compound of structural formula (I):



wherein R¹ is selected from the group consisting of C₁₂- to C₁₆-alkyl and C₁₂- to C₁₆-

alkene, ~~and R², R⁸, R⁹ and R¹⁰ are hydrogen:~~

R² is selected from the group consisting of hydrogen, and C₁- to C₆-alkyl;

R³ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁴ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁵ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, and I;

R⁶ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN;

R⁷ is selected from the group consisting of hydrogen, C₁- to C₆-alkyl, CF₃, CCl₃, Cl₃, F, Cl, I, and CN; and

R⁸, R⁹, and R¹⁰ are independently selected from the group consisting of hydrogen, C₁- to C₁₆-alkyl, C₁- to C₁₆-alkene, and C₁- to C₁₆-alkoxy; and salts thereof.

10. – 13. (CANCELED)

14. (PREVIOUSLY PRESENTED) A pharmaceutical composition for treating cancer, acquired immune deficiency syndrome (AIDS), HIV infection, and asthma, the composition comprising an anti-cancer-, anti-AIDS-, anti-HIV- or anti-asthma-effective amount of a compound of claim 5 or a pharmaceutically suitable salt thereof, in combination with a pharmaceutically suitable carrier.

15. (CANCELED)

16. (CANCELED)